KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Cost of Revenue (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cost of Revenue for 16 consecutive years, with $78.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 87.3% to $78.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.8 million, a 43.51% increase, with the full-year FY2025 number at $228.8 million, up 43.51% from a year prior.
  • Cost of Revenue was $78.8 million for Q4 2025 at Halozyme Therapeutics, up from $55.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $78.8 million in Q4 2025 to a low of $15.9 million in Q1 2022.
  • A 5-year average of $40.1 million and a median of $42.1 million in 2022 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 301.01% in 2021, then decreased 20.9% in 2024.
  • Halozyme Therapeutics' Cost of Revenue stood at $21.6 million in 2021, then soared by 95.12% to $42.1 million in 2022, then grew by 24.16% to $52.3 million in 2023, then decreased by 19.59% to $42.1 million in 2024, then surged by 87.3% to $78.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Cost of Revenue are $78.8 million (Q4 2025), $55.2 million (Q3 2025), and $46.4 million (Q2 2025).